| Revenue | 20,748.55a | 19,532.2a |
| Cost of sales | -6,983.75a | -6,868.85a |
| Gross profit | 13,764.8a | 12,663.35a |
| Other income and gains, net | 1,465.06a | 1,659.53a |
| Selling and distribution expenses | -7,181.22a | -6,709.07a |
| Administrative expenses | -1,681.26a | -1,762.05a |
| Other expenses | -146.32a | -100.86a |
| Finance costs | -44.65a | -53.13a |
| Share of losses of associates | -8.91a | -5.96a |
| Share of loss of a joint venture | -3.27a | -1.45a |
| Impairment losses on property, plant and equipment and right-of-use assets | 0a | -89.81a |
| Changes in fair value less costs to sell of biological assets | -614.5a | -750.26a |
| Profit before tax | 5,549.73a | 4,850.29a |
| Income tax expense | -1,895.61a | -1,559.94a |
| Profit for the year | 3,654.12a | 3,290.35a |
| Attributable to | — | — |
| Owners of the parent | 3,570.13a | 3,390.01a |
| Non-controlling interests | 84a | -99.66a |